These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 8626121)
21. Antisense targeting human papillomavirus type 16 E6 and E7 genes contributes to apoptosis and senescence in SiHa cervical carcinoma cells. Sima N; Wang S; Wang W; Kong D; Xu Q; Tian X; Luo A; Zhou J; Xu G; Meng L; Lu Y; Ma D Gynecol Oncol; 2007 Aug; 106(2):299-304. PubMed ID: 17586029 [TBL] [Abstract][Full Text] [Related]
22. Comparison of peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 proteins. Sun Y; Shah KV; Müller M; Muñoz N; Bosch XF; Viscidi RP J Clin Microbiol; 1994 Sep; 32(9):2216-20. PubMed ID: 7529250 [TBL] [Abstract][Full Text] [Related]
23. The relationship between cytokines and HPV-16, HPV-16 E6, E7, and high-risk HPV viral load in the uterine cervix. Song SH; Lee JK; Seok OS; Saw HS Gynecol Oncol; 2007 Mar; 104(3):732-8. PubMed ID: 17188341 [TBL] [Abstract][Full Text] [Related]
24. Association of serum antibodies against defined epitopes of human papillomavirus L1, E2, and E7 antigens and of HPV DNA with incident cervical cancer. Dillner L; Zellbi A; Avall-Lundqvist E; Heino P; Eklund C; Pettersson CA; Forslund O; Hansson BG; Grandien M; Bistoletti P Cancer Detect Prev; 1995; 19(5):381-93. PubMed ID: 7585724 [TBL] [Abstract][Full Text] [Related]
26. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268 [TBL] [Abstract][Full Text] [Related]
27. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Nguyen HH; Broker TR; Chow LT; Alvarez RD; Vu HL; Andrasi J; Brewer LR; Jin G; Mestecky J Gynecol Oncol; 2005 Feb; 96(2):452-61. PubMed ID: 15661235 [TBL] [Abstract][Full Text] [Related]
28. Identification of antibodies against human papillomavirus type 16 E4 and E7 proteins in sera of patients with cervical neoplasias. Stoian M; Repanovici R Rev Roum Virol; 1994; 45(3-4):185-92. PubMed ID: 7619739 [TBL] [Abstract][Full Text] [Related]
29. Immunologic diagnosis and monitoring of cervical cancers using in vitro translated HPV proteins. Chee YH; Namkoong SE; Kim DH; Kim SJ; Park JS Gynecol Oncol; 1995 May; 57(2):226-31. PubMed ID: 7729739 [TBL] [Abstract][Full Text] [Related]
30. HPV 16 E7 antibody levels in cervical cancer patients: before and after treatment. Di Lonardo A; Marcante ML; Poggiali F; Venuti A J Med Virol; 1998 Mar; 54(3):192-5. PubMed ID: 9515768 [TBL] [Abstract][Full Text] [Related]
31. Frequent display of human papillomavirus type 16 E6-specific memory t-Helper cells in the healthy population as witness of previous viral encounter. Welters MJ; de Jong A; van den Eeden SJ; van der Hulst JM; Kwappenberg KM; Hassane S; Franken KL; Drijfhout JW; Fleuren GJ; Kenter G; Melief CJ; Offringa R; van der Burg SH Cancer Res; 2003 Feb; 63(3):636-41. PubMed ID: 12566307 [TBL] [Abstract][Full Text] [Related]
32. Physical status and expression of HPV genes in cervical cancers. Park JS; Hwang ES; Park SN; Ahn HK; Um SJ; Kim CJ; Kim SJ; Namkoong SE Gynecol Oncol; 1997 Apr; 65(1):121-9. PubMed ID: 9103401 [TBL] [Abstract][Full Text] [Related]
33. Detection of human papillomavirus DNA, serum p53, and p53 antibodies in patients with cervical cancer. Sobti RC; Parashar K; Kaur R; Capalash N J Environ Pathol Toxicol Oncol; 2002; 21(1):79-85. PubMed ID: 11934017 [TBL] [Abstract][Full Text] [Related]
34. [Expression, purification, and serum antibody detection of HPV16 E6 in cervical cancer patients]. Gao YE; Guo JZ; Zhang J; Song TB; Yan XJ Ai Zheng; 2006 Nov; 25(11):1374-9. PubMed ID: 17094904 [TBL] [Abstract][Full Text] [Related]
35. [Association between human papillomavirus (HPV) type 16 infection and E6/E7 gene variant and the cervical lesions in Beijing]. Yang YJ; Zhao J; Liao QP Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2007 Mar; 21(1):32-4. PubMed ID: 17429529 [TBL] [Abstract][Full Text] [Related]
36. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Wadler S; Levy D; Frederickson HL; Falkson CI; Wang Y; Weller E; Burk R; Ho G; Kadish AS; Gynecol Oncol; 2004 Mar; 92(3):957-64. PubMed ID: 14984966 [TBL] [Abstract][Full Text] [Related]
37. Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins. Yugawa T; Kiyono T Rev Med Virol; 2009 Mar; 19(2):97-113. PubMed ID: 19156753 [TBL] [Abstract][Full Text] [Related]
38. [Expression purification and clinical application of high-risk HPV16 E4 gene]. Gao YE; Hui H; Zhang J; Fan JB; Yan XJ Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Aug; 33(8):676-81. PubMed ID: 18772505 [TBL] [Abstract][Full Text] [Related]
39. [Relationship between human papillomavirus E7 protein and Rb gene product in fresh tissues of squamous cervical carcinoma]. Wang P; Peng Z; Wang H Zhonghua Fu Chan Ke Za Zhi; 1997 Dec; 32(12):722-4. PubMed ID: 9772434 [TBL] [Abstract][Full Text] [Related]